| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.8 | 7.8 |
| Gross profit | 5.1 | 3.6 |
| Profit before tax | -5.3 | -6.6 |
| Net income | -4.5 | -5.9 |
| EPS (diluted, $ a share) | $-0.10 | $-0.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +25.5% |
|---|---|
| Gross margin | 51.4% |
| Operating margin | -79.1% |
10-Q filed with the SEC, NASDAQ: FOCL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Edap Tms SA: key numbers
- Share price
- $3.17Close, Nov 16
- Market cap
- $150M
- Shares outstanding
- 47.22MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Edap Tms SA
All →Edap Tms Financial Results
EDAP TMS (FocalTherics) reported Q3 2026 revenue of $9.8 million, a 26% increase year-over-year, driven by a 32% increase in U.S. procedure volume and seven Focal One system sales. The company narrowed its full-year 2026 revenue guidance to $50.0-$52.0 million, representing 34% to 39% growth over 2025.
- Term
- Q3 2026
“We demonstrated steady commercial momentum in the third quarter, highlighted by expanding adoption across multiple new regions and additional system sales in the United States, Turkey, Mexico, and France. U.S. procedure volumes accelerated year-over-year to 32% for the third quarter of 2026, compared to 15% in 2025. Driven by our sustained commercial traction, accelerating technology adoption, and our focus on our HIFU opportunity, we remain highly confident in our growth strategy and on the opportunity ahead as we close out the year.”
Ryan Rhodes, CEO of FocalTherics